Botulinum Toxin Type A for Painful Temporomandibular Disorders: Systematic Review and Meta-Analysis

Machado, Daniel Gomes da Silva; Martimbianco, Ana Luiza Cabrera; Bussadori, Sandra Kalil; Pacheco, Rafael Leite; Riera, Rachel; Santos, Elaine Marcílio

doi:10.1016/j.jpain.2019.08.011

Cited by 34 publications

(35 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Homogeneity test (Q test) and I 2 value was used to test the heterogeneity of the included research. When the heterogeneity test result is P>0.1 and I 2 <50%, the heterogeneity of the research is considered to be acceptable, and then the fixed effects model is adopted; otherwise the random effects model is adopted ( 9 ). (1) A random effects model was used to combine the included studies on the rate of CSM after NAC, calculate the rate of CSM and 95% CI, perform the sensitivity analysis with one-by-one elimination, and determine the publication bias of the study by using the funnel plot and Egger’s test ( 8 ).…”

Section: Methodsmentioning

confidence: 99%

Meta-Analysis of Shrinkage Mode After Neoadjuvant Chemotherapy for Breast Cancers: Association With Hormonal Receptor

Zheng

Shan

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundPatients with concentric shrinkage mode after neoadjuvant chemotherapy (NAC) is considered to be ideal candidates for breast conserving treatment (BCT). While, what proportion of patients would represent CSM have not been well defined. This study was conducted to pool the rates of concentric shrinkage mode (CSM) in patients undergoing NAC, determine the impact of hormonal receptor on the shrinkage mode after NAC and estimate the rates of the CSM in various subgroups.MethodsWe conducted a systematic review following the guidelines for Meta-Analyses and Systematic reviews for the PRISMA guidelines. We systematically searched the literature about shrinkage mode after NAC from PubMed, Web of Science, Embase, The Cochrane Library, CNKI, Wanfang database published from January 2002 to June 2020 on breast cancer shrinkage mode after NAC and carefully screened the literature by using eligibility criteria: (1) patients with primary breast cancer treated with NAC; (2) publications with available data of shrinkage mode measured by magnetic resonance imaging (MRI), or data of pathology and hormonal receptor. The association between shrinkage mode and hormonal receptor was estimated using Stata 15.1 software.ResultsThis analysis included a total of 2434 tumors from 23 papers. The included studies were heterogeneous (I2 = 89.4%, P<0.01). Random effects model was used to estimate the overall rates of CSM: 56.6% [95%CI (50.5%, 62.7%)]. According to the analysis of hormonal receptor, 10 of the paper was included for HR+ (hormone receptor positive) type analysis and the rate of CSM for HR+ type was 45.7% [95%CI (36.4%, 55.0%)]; 9 of the paper was used for HR- type (hormone receptor negative) analysis and the incidence of HR-CSM is 63.1% [95%CI (50.0%, 76.1%)]; with HR+ type as the control, the OR of the HR- CSM rate is 2.32 (1.32, 4.08) folds of HR+ type. From subgroup analyses, the CSM% of luminal A, luminal B, Her2+, and triple negative were 29.7% (16.5%, 42.8%); 47.2% (19.1%, 75.3%); 59.0% (39.7%, 78.3%); 66.2% (52.8%, 79.6%), respectively.ConclusionsBreast cancer patients undergoing NAC did not get an ideal odds ratio of CSM. The incidence of CSM in breast cancer after NAC is associated with hormonal receptor. Patients with triple-negative breast cancers have the highest rates of CSM after NAC. More care should be taken to select patients with the luminal subtypes for BCT throughout NAC.

show abstract

Section: Methodsmentioning

confidence: 99%

Meta-Analysis of Shrinkage Mode After Neoadjuvant Chemotherapy for Breast Cancers: Association With Hormonal Receptor

Zheng

Shan

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The safety profile of BoNT-A was assessed in four meta-analyses for trigeminal neuralgia [83], painful temporomandibular disorders [84], upper limb spasticity after stroke and traumatic brain injury [85], and overactive bladder [86]. None of these metaanalyses found significant adverse effects related to BoNT-A injections between BoNT-A and placebo groups [83][84][85][86].…”

Section: Botulinum Toxin (Bont)mentioning

confidence: 99%

The Safety of Medications used to Treat Peripheral Neuropathic Pain, Part 2 (Opioids, Cannabinoids and Other Drugs): review of Double-Blind, Placebo-Controlled, Randomized Clinical Trials

Cuménal

Selvy

Kerckhove

et al. 2020

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires

show abstract

“…Machado et al, [63] in their recent systematic review have shown that injection of Botulinum toxin type A for painful TMJ disorders was well tolerated and was more effective in pain reduction compared to placebo and other treatment modalities. Patel et al, [64] have recommended considering the use of Botulinum toxin for TMD's only after exhaustion of other conservative measures.…”

Section: Botulinum Toxin Type a Injectionmentioning

confidence: 99%

Pain Management in Temporomandibular Disorders: A Review of the Literature

Melek¹,

Renton²

2020

SJODR

View full text Add to dashboard Cite

Botulinum Toxin Type A for Painful Temporomandibular Disorders: Systematic Review and Meta-Analysis

Cited by 34 publications

References 41 publications

Meta-Analysis of Shrinkage Mode After Neoadjuvant Chemotherapy for Breast Cancers: Association With Hormonal Receptor

Meta-Analysis of Shrinkage Mode After Neoadjuvant Chemotherapy for Breast Cancers: Association With Hormonal Receptor

The Safety of Medications used to Treat Peripheral Neuropathic Pain, Part 2 (Opioids, Cannabinoids and Other Drugs): review of Double-Blind, Placebo-Controlled, Randomized Clinical Trials

Pain Management in Temporomandibular Disorders: A Review of the Literature

Contact Info

Product

Resources

About